



BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference

January 7, 2025

RESEARCH TRIANGLE PARK, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](#) (Nasdaq: BCRX) today announced that the company will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2025, at 6:00 p.m. ET.

Link to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst's website at www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO[®] (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on [LinkedIn](#).

BCRXW

Contact:

John Bluth
+1 919 859 7910
jbluth@biocryst.com